Special Issue

Anti-Cancer Drug: Discovery, Development and Combination

Message from the Guest Editor

Cancer is recognized as a multifactorial disease and its progression is regulated by extremely complex mechanisms. Furthermore, the contribution of such carcinogenic factors to malignant behavior is dependent on the type of cancer and the stage of the disease.

Armed with this knowledge, researchers have discovered many promising candidates for cancer therapy, and some are now being tested in clinical trials. Various new therapeutic targets, including chemical compounds and natural products, have been identified from basic and translational studies.

The aim of this Special Issue is to collect research papers, reviews, and communications focused on the discovery and development of anti-cancer drugs, as well as potential therapeutic targets, for various types of cancers. Moreover, clinical and translational studies on anti-cancer drugs used to improve the efficacy of conservative therapies, to decrease the number of residual cancer cells after operation, and to maintain the quality of life in patients with cancer, are invited.

Guest Editor

Dr. Yasuyoshi Miyata

Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Deadline for manuscript submissions

closed (31 March 2020)

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/si/26149

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/journal/molecules

MDPI

About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt
Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).